Cargando…
Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of unknown etiology. The course of the disease cannot be predicted with certainty. It is crucial to regularly monitor the disease using multiple assessments to evaluate its progression. Currently, there is no con...
Autores principales: | Cilli, Aykut, Uzer, Fatih |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540722/ https://www.ncbi.nlm.nih.gov/pubmed/37712374 http://dx.doi.org/10.36141/svdld.v40i3.14048 |
Ejemplares similares
-
Acute asthma exacerbation after SARS-CoV-2 vaccine (Sinovac(®)): a case report
por: Uzer, Fatih, et al.
Publicado: (2021) -
Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022) -
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019) -
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
por: Khor, Yet H., et al.
Publicado: (2020) -
Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)